Hoskuld
18 minutes ago
The UK likes medicines that work, and, as you know, NWBO's candidate provides very questionable value. I think comparing NWBO's NIH application to AVXL's EMA application is not great. AVXL seems to have pretty incontrovertible evidence that 2-73 really works for AD - in the short term and the long